Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without ATRA in unfit AML or high-risk MDS
NCT05175508Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tretinoin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
tretinoin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05175508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175508.